{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:57:10Z","timestamp":1740182230283,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["MOST 111-2740-B-037-001","MOST111-2314-B-037-063"],"award-info":[{"award-number":["MOST 111-2740-B-037-001","MOST111-2314-B-037-063"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p><jats:italic>Indigofera suffruticosa<\/jats:italic> Mill. is used as a folk medicine for treating patients with leukemia, however very little is known regarding the molecular mechanism of its anti-leukemic activity and the chemical profile of the active extract. The present study aimed to reveal the molecular effect of <jats:italic>I. suffruticosa<\/jats:italic> aerial parts extract (ISAE) on leukemia cells and its chemical constituents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cytotoxicity of ISAE were determined by resazurin viability assay, multitox \u2013 Glo multiplex cytotoxicity assay, and Annexin V staining assay. Cell cycle profiles were revealed by propidium iodide staining assay. The effects of ISAE on G2\/M arrest signaling and DNA damage were evaluated by Western blot assay and phospho-H2A.X staining assay. The chemical profile of ISAE were determined by tandem mass spectroscopy and molecular networking approach.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We showed that the acute lymphoblastic leukemia cell line Jurkat cell was more responsive to ISAE treatment than other leukemia cell lines. In contrast, ISAE did not induce cytotoxic effects in normal fibroblast cells. Cell cycle analysis revealed that ISAE triggered G2\/M arrest in Jurkat cells in dose- and time-dependent manners. Elevation of annexin V-stained cells and caspase 3\/7 activity suggested ISAE-induced apoptosis. Furthermore, ISAE alone could increase the phosphorylation of CDK1 at Y15 and activate the ATR\/CHK1\/Wee1\/CDC25C signaling pathway. However, the addition of caffeine, a widely used ATR inhibitor to ISAE, reduced the phosphorylation of ATR, CHK1, and CDK1, as well as G2\/M arrest in Jurkat cells. Moreover, increased phospho-H2A.X stained cells indicated the involvement of DNA damage in the anti-leukemic effect of ISAE. Finally, qualitative analysis using UPLC-tandem mass spectroscopy and molecular networking revealed that tryptanthrin was the most abundant organoheterocyclic metabolite in ISAE. At equivalent concentrations to ISAE, tryptanthrin induced G2\/M arrest of Jurkat cells, which can be prevented by caffeine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ISAE causes G2\/M arrest via activating ATR\/CHK1\/CDK1 pathway and tryptanthrin is one of the active components of ISAE. Our findings provide subtle support to the traditional use of <jats:italic>I. suffruitcosa<\/jats:italic> in leukemia management in folk medicine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-023-04325-w","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T10:04:05Z","timestamp":1704794645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Indigofera suffruticosa aerial parts extract induce G2\/M arrest and ATR\/CHK1 pathway in Jurkat cells"],"prefix":"10.1186","volume":"24","author":[{"given":"Hong-Loan","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuei-Hung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsun-Shuo","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Siao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuen-Shin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsueh-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Mu","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hung","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Hua","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"10230","key":"4325_CR1","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146\u201362.","journal-title":"Lancet"},{"issue":"11","key":"4325_CR2","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s10552-015-0657-6","volume":"26","author":"AJ Katz","year":"2015","unstructured":"Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control. 2015;26(11):1627\u201342.","journal-title":"Cancer Causes Control"},{"key":"4325_CR3","unstructured":"American Cancer Society. Key Statistics for Acute Lymphocytic Leukemia (ALL). https:\/\/www.cancer.org\/cancer\/types\/acute-lymphocytic-leukemia\/about\/key-statistics.html. Accessed: 21 Sep 2023."},{"issue":"1","key":"4325_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","volume":"13","author":"B Samra","year":"2020","unstructured":"Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13(1):70.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"4325_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","volume":"83","author":"DJ Newman","year":"2020","unstructured":"Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019. J Nat Prod. 2020;83(3):770\u2013803.","journal-title":"J Nat Prod"},{"issue":"6","key":"4325_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/bph.14943","volume":"177","author":"EM Williamson","year":"2020","unstructured":"Williamson EM, Liu X, Izzo AA. Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals. Br J Pharmacol. 2020;177(6):1227\u201340.","journal-title":"Br J Pharmacol"},{"key":"4325_CR7","first-page":"8168526","volume":"2018","author":"JKL Campos","year":"2018","unstructured":"Campos JKL, Araujo T, Brito T, da Silva APS, da Cunha RX, Martins MB, da Silva NH, Dos Santos BS, da Silva CA, Lima VLM. Indigofera suffruticosa Mill. (Anil): plant profile, phytochemistry, and pharmacology review. Adv Pharmacol Sci. 2018;2018:8168526.","journal-title":"Adv Pharmacol Sci"},{"key":"4325_CR8","volume-title":"The catalogue of medicinal plant resources in Taiwan","author":"JC Ou","year":"2003","unstructured":"Ou JC, Hsieh WC, Lin IH, Chang YS, Chen IS. The catalogue of medicinal plant resources in Taiwan. Taiwan: Department of Health, Executive Yuan, Taiwan; 2003."},{"issue":"1","key":"4325_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2119\/molmed.2011.00331","volume":"18","author":"CH Yen","year":"2012","unstructured":"Yen CH, Lu YC, Li CH, Lee CM, Chen CY, Cheng MY, Huang SF, Chen KF, Cheng AL, Liao LY, et al. Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6\/DEPTOR in hepatocellular carcinoma. Mol Med. 2012;18(1):286\u201396.","journal-title":"Mol Med"},{"issue":"9","key":"4325_CR10","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/antiox11091813","volume":"11","author":"W Liu","year":"2022","unstructured":"Liu W, Hsu YY, Tang JY, Cheng YB, Chuang YT, Jeng JH, Yen CH, Chang HW. Methanol extract of commelina plant inhibits oral cancer cell proliferation. Antioxidants. 2022;11(9):1813.","journal-title":"Antioxidants"},{"issue":"4","key":"4325_CR11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/antiox10040544","volume":"10","author":"YS Chen","year":"2021","unstructured":"Chen YS, Chang HS, Hsiao HH, Chen YF, Kuo YP, Yen FL, Yen CH. Identification of Beilschmiedia Tsangii root extract as a liver cancer cell-normal keratinocyte dual-selective NRF2 regulator. Antioxidants. 2021;10(4):544.","journal-title":"Antioxidants"},{"issue":"9","key":"4325_CR12","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3390\/antiox11091755","volume":"11","author":"SH Wang","year":"2022","unstructured":"Wang SH, Chen YS, Lai KH, Lu CK, Chang HS, Wu HC, Yen FL, Chen LY, Lee JC, Yen CH. Prinsepiae nux extract activates NRF2 activity and protects UVB-Induced damage in keratinocyte. Antioxidants. 2022;11(9):1755.","journal-title":"Antioxidants"},{"issue":"4","key":"4325_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/cancers13040795","volume":"13","author":"L Gorecki","year":"2021","unstructured":"Gorecki L, Andrs M, Korabecny J. Clinical candidates targeting the ATR-CHK1-WEE1 axis in cancer. Cancers. 2021;13(4):795.","journal-title":"Cancers"},{"key":"4325_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.biopha.2018.05.144","volume":"105","author":"G Tej","year":"2018","unstructured":"Tej G, Nayak PK. Mechanistic considerations in chemotherapeutic activity of caffeine. Biomed Pharmacother. 2018;105:312\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"4325_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 2017;66(6):801\u201317.","journal-title":"Mol Cell"},{"issue":"3","key":"4325_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4161\/cbt.2.3.373","volume":"2","author":"OA Sedelnikova","year":"2003","unstructured":"Sedelnikova OA, Pilch DR, Redon C, Bonner WM. Histone H2AX in DNA damage and repair. Cancer Biol Ther. 2003;2(3):233\u20135.","journal-title":"Cancer Biol Ther"},{"issue":"14","key":"4325_CR17","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.3390\/molecules25143223","volume":"25","author":"K Lech","year":"2020","unstructured":"Lech K, Fornal E. A mass spectrometry-based approach for characterization of red, blue, and purple natural dyes. Molecules. 2020;25(14):3223.","journal-title":"Molecules"},{"issue":"7","key":"4325_CR18","doi-asserted-by":"publisher","first-page":"e9037","DOI":"10.1002\/rcm.9037","volume":"35","author":"R Molino","year":"2021","unstructured":"Molino R, Junio HA. Profiling the Philippine Blue: liquid chromatography\/mass spectrometry-based metabolomics study on Philippine Indigofera. Rapid Commun Mass Spectrom. 2021;35(7):e9037.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"4325_CR19","doi-asserted-by":"publisher","first-page":"112504","DOI":"10.1016\/j.ejmech.2020.112504","volume":"202","author":"E Catanzaro","year":"2020","unstructured":"Catanzaro E, Betari N, Arencibia JM, Montanari S, Sissi C, De Simone A, Vassura I, Santini A, Andrisano V, Tumiatti V, et al. Targeting topoisomerase II with trypthantrin derivatives: discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer. Eur J Med Chem. 2020;202:112504.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"4325_CR20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bmcl.2012.12.006","volume":"23","author":"J Song","year":"2013","unstructured":"Song J, Kitamatsu M, Imamura K, Ohmori H, Watanabe K, Nakanishi K. On the preparation of indoxyl red from indican and some new characteristics. Bioorg Med Chem Lett. 2013;23(3):627\u20139.","journal-title":"Bioorg Med Chem Lett"},{"key":"4325_CR21","doi-asserted-by":"publisher","first-page":"664022","DOI":"10.3389\/fphar.2021.664022","volume":"12","author":"Q Sun","year":"2021","unstructured":"Sun Q, Leng J, Tang L, Wang L, Fu C. A comprehensive review of the chemistry, pharmacokinetics, pharmacology, clinical applications, adverse events, and quality control of Indigo Naturalis. Front Pharmacol. 2021;12:664022.","journal-title":"Front Pharmacol"},{"key":"4325_CR22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/978-3-642-73739-8_103","volume-title":"Chinese drugs of plant origin","author":"W Tang","year":"1992","unstructured":"Tang W, Eisenbrand G. Qingdai. In: Tang W, Eisenbrand G, editors. Chinese drugs of plant origin. Berlin: Springer Berlin Heidelberg; 1992. p. 805\u201312."},{"issue":"3","key":"4325_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3390\/plants9030298","volume":"9","author":"J Speranza","year":"2020","unstructured":"Speranza J, Miceli N, Taviano MF, Ragusa S, Kwiecien I, Szopa A, Ekiert H. Isatis tinctoria L. (woad): a review of its botany, ethnobotanical uses, phytochemistry, biological activities, and biotechnological studies. Plants (Basel). 2020;9(3):298.","journal-title":"Plants (Basel)"},{"key":"4325_CR24","doi-asserted-by":"publisher","first-page":"113112","DOI":"10.1016\/j.biopha.2022.113112","volume":"151","author":"L Yang","year":"2022","unstructured":"Yang L, Li X, Huang W, Rao X, Lai Y. Pharmacological properties of indirubin and its derivatives. Biomed Pharmacother. 2022;151:113112.","journal-title":"Biomed Pharmacother"},{"key":"4325_CR25","doi-asserted-by":"publisher","first-page":"25491","DOI":"10.1038\/srep25491","volume":"6","author":"X Wu","year":"2016","unstructured":"Wu X, Chen X, Dan J, Cao Y, Gao S, Guo Z, Zerbe P, Chai Y, Diao Y, Zhang L. Characterization of anti-leukemia components from indigo naturalis using comprehensive two-dimensional K562\/cell membrane chromatography and in silico target identification. Sci Rep. 2016;6:25491.","journal-title":"Sci Rep"},{"issue":"1","key":"4325_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/9035","volume":"1","author":"R Hoessel","year":"1999","unstructured":"Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999;1(1):60\u20137.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"4325_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00432-004-0579-2","volume":"130","author":"G Eisenbrand","year":"2004","unstructured":"Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol. 2004;130(11):627\u201335.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"4325_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1054\/bjoc.2000.1546","volume":"84","author":"D Marko","year":"2001","unstructured":"Marko D, Schatzle S, Friedel A, Genzlinger A, Zankl H, Meijer L, Eisenbrand G. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer. 2001;84(2):283\u20139.","journal-title":"Br J Cancer"},{"issue":"3","key":"4325_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.molonc.2012.02.002","volume":"6","author":"S Nam","year":"2012","unstructured":"Nam S, Scuto A, Yang F, Chen W, Park S, Yoo HS, Konig H, Bhatia R, Cheng X, Merz KH, et al. Indirubin derivatives induce apoptosis of chronic myelogenous Leukemia cells involving inhibition of Stat5 signaling. Mol Oncol. 2012;6(3):276\u201383.","journal-title":"Mol Oncol"},{"issue":"5","key":"4325_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/cmi.2009.44","volume":"6","author":"HL Chan","year":"2009","unstructured":"Chan HL, Yip HY, Mak NK, Leung KN. Modulatory effects and action mechanisms of tryptanthrin on murine myeloid leukemia cells. Cell Mol Immunol. 2009;6(5):335\u201342.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"4325_CR31","doi-asserted-by":"publisher","first-page":"e110411","DOI":"10.1371\/journal.pone.0110411","volume":"9","author":"AS Pathania","year":"2014","unstructured":"Pathania AS, Kumar S, Guru SK, Bhushan S, Sharma PR, Aithagani SK, Singh PP, Vishwakarma RA, Kumar A, Malik F. The synthetic tryptanthrin analogue suppresses STAT3 signaling and induces caspase dependent apoptosis via ERK up regulation in human leukemia HL-60 cells. PLoS ONE. 2014;9(11):e110411.","journal-title":"PLoS ONE"},{"issue":"11","key":"4325_CR32","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/biomedicines9111527","volume":"9","author":"JY Gao","year":"2021","unstructured":"Gao JY, Chang CS, Lien JC, Chen TW, Hu JL, Weng JR. Synthetic tryptanthrin derivatives induce cell cycle arrest and apoptosis via akt and MAPKs in human hepatocellular carcinoma cells. Biomedicines. 2021;9(11):1527.","journal-title":"Biomedicines"},{"issue":"6","key":"4325_CR33","first-page":"2426","volume":"42","author":"M Yang","year":"2019","unstructured":"Yang M, Tian X, Fan Z, Yu W, Li Z, Zhou J, Zhang W, Liang A. Targeting RAD51 enhances chemosensitivity of adult T\u2013cell leukemia\u2013lymphoma cells by reducing DNA double\u2013strand break repair. Oncol Rep. 2019;42(6):2426\u201334.","journal-title":"Oncol Rep"},{"issue":"6","key":"4325_CR34","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1159\/000493815","volume":"49","author":"W Yu","year":"2018","unstructured":"Yu W, Li L, Wang G, Zhang W, Xu J, Liang A. KU70 inhibition impairs both non-homologous end joining and homologous recombination DNA damage repair through SHP-1 induced dephosphorylation of SIRT1 in T-cell acute lymphoblastic leukemia (T-ALL) [corrected]. Cell Physiol Biochem. 2018;49(6):2111\u201323.","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"4325_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1046\/j.1440-1827.2001.01204.x","volume":"51","author":"T Kimoto","year":"2001","unstructured":"Kimoto T, Hino K, Koya-Miyata S, Yamamoto Y, Takeuchi M, Nishizaki Y, Micallef MJ, Ushio S, Iwaki K, Ikeda M, et al. Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U-937 and HL-60) by tryptanthrin, an active ingredient of Polygonum Tinctorium Lour. Pathol Int. 2001;51(5):315\u201325.","journal-title":"Pathol Int"},{"issue":"3","key":"4325_CR36","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10565-021-09640-x","volume":"39","author":"A Di Ghelli Luserna","year":"2023","unstructured":"Di Ghelli Luserna A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, Napolitano R, Fontana MC, Liverani C, Imbrogno E, et al. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. Cell Biol Toxicol. 2023;39(3):795\u2013811.","journal-title":"Cell Biol Toxicol"},{"issue":"3","key":"4325_CR37","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3390\/ijms22031223","volume":"22","author":"J Hur","year":"2021","unstructured":"Hur J, Ghosh M, Kim TH, Park N, Pandey K, Cho YB, Hong SD, Katuwal NB, Kang M, An HJ, et al. Synergism of AZD6738, an ATR inhibitor, in combination with belotecan, a camptothecin analogue, in chemotherapy-resistant ovarian cancer. Int J Mol Sci. 2021;22(3):1223.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4325_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","volume":"19","author":"AM Wengner","year":"2020","unstructured":"Wengner AM, Siemeister G, Lucking U, Lefranc J, Wortmann L, Lienau P, Bader B, Bomer U, Moosmayer D, Eberspacher U, et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models. Mol Cancer Ther. 2020;19(1):26\u201338.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"4325_CR39","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","volume":"20","author":"U Jo","year":"2021","unstructured":"Jo U, Senatorov IS, Zimmermann A, Saha LK, Murai Y, Kim SH, Rajapakse VN, Elloumi F, Takahashi N, Schultz CW, et al. Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents. Mol Cancer Ther. 2021;20(8):1431\u201341.","journal-title":"Mol Cancer Ther"},{"key":"4325_CR40","doi-asserted-by":"publisher","first-page":"107450","DOI":"10.1016\/j.pharmthera.2019.107450","volume":"207","author":"A Bradbury","year":"2020","unstructured":"Bradbury A, Hall S, Curtin N, Drew Y. Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations? Pharmacol Ther. 2020;207:107450.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"4325_CR41","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1080\/10428194.2017.1335397","volume":"59","author":"A Kansagra","year":"2018","unstructured":"Kansagra A, Dahiya S, Litzow M. Continuing challenges and current issues in acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(3):526\u201341.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"4325_CR42","doi-asserted-by":"publisher","first-page":"E245","DOI":"10.1002\/ajh.25896","volume":"95","author":"B Samra","year":"2020","unstructured":"Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, Jain N, Konopleva M, Kantarjian H, Jabbour E. Outcome of adults with relapsed\/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020;95(9):E245-247.","journal-title":"Am J Hematol"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-04325-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-023-04325-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-023-04325-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T11:02:49Z","timestamp":1704798169000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-023-04325-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4325"],"URL":"https:\/\/doi.org\/10.1186\/s12906-023-04325-w","relation":{},"ISSN":["2662-7671"],"issn-type":[{"type":"electronic","value":"2662-7671"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods conducted comply with relevant institutional, national, and international guidelines and legislation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}